NCT04614441

NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib

Non-Interventional Collecting Evidences For ILD in Taiwan: Optimized Novel Therapy

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 214 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

To better understand the clinical characteristics of Idiopathic Pulmonary Fibrosis (IPF) / Systemic Sclerosis-associated-Interstitial Lung Disease (SSc-ILD)/ Progressive Fibrosing Interstitial Lung Disease (PF-ILD) patients treated with nintedanib and biomarkers associated with the disease course, a non-interventional, 3-year, prospective study will be conducted to collect the long-term real-world clinical data on IPF/SSc-ILD/PF-ILD patients newly administered with nintedanib in Taiwan

Conditions

• Idiopathic Pulmonary Fibrosis

Interventions

Type	Name	Description
DRUG	OFEV®	nintedanib

Timeline

• Start date: 2021-01-21
• Primary completion: 2025-05-14
• Completion: 2025-05-14
• First posted: 2020-11-04
• Last updated: 2025-08-19

Locations

26 sites across 1 country: Taiwan

Regulatory

• FDA-regulated drug study